Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
Neuroscience
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April...
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -CAMBRIDGE, Mass., April 05, 2023 (GLOBE...
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place...
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a...
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness...
Aurora Spine Receives IRB Multi-Site Selection Approval for its DEXA-C™ Cervical Interbody System
Patient enrollment to commenceCarlsbad, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG)...
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission...
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma”...
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases...
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for...
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health...
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline...
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2...
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...